Terms: = Brain cancer AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1
34 results:
1. In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors.
Ni S; Li L; Sun X; Wang Y; Yu Q; Wang W; Gu Z; Yu Z; Wu D; Wu F; Jiang S; Peng P
Eur J Pharm Sci; 2024 Jan; 192():106658. PubMed ID: 38048851
[TBL] [Abstract] [Full Text] [Related]
2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for cyp2d6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
Bousman CA; Stevenson JM; Ramsey LB; Sangkuhl K; Hicks JK; Strawn JR; Singh AB; Ruaño G; Mueller DJ; Tsermpini EE; Brown JT; Bell GC; Leeder JS; Gaedigk A; Scott SA; Klein TE; Caudle KE; Bishop JR
Clin Pharmacol Ther; 2023 Jul; 114(1):51-68. PubMed ID: 37032427
[TBL] [Abstract] [Full Text] [Related]
3. Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects.
Keller DN; Medwid SJ; Ross CD; Wigle TJ; Kim RB
Pharmacogenet Genomics; 2023 Jan; 33(1):10-18. PubMed ID: 36373739
[TBL] [Abstract] [Full Text] [Related]
4. Preclinical pharmacokinetics, CYP phenotyping, and tissue distribution study of novel anti-breast cancer candidate S-011-1559.
Verma SK; Biswas A; Kumar M; Mishra A; Choudhury AD; Agrawal S; Sanap SN; Bisen AC; Sharma AK; Panda G; Bhatta RS
Xenobiotica; 2022 May; 52(5):476-487. PubMed ID: 35819259
[TBL] [Abstract] [Full Text] [Related]
5. Identification of novel natural inhibitors targeting AKT Serine/Threonine Kinase 1 (AKT1) by computational study.
Zhong S; Zhang Z; Guo Z; Yang W; Dou G; Lv X; Wang X; Ge J; Wu B; Pan X; Wang H; Mou Y
Bioengineered; 2022 May; 13(5):12003-12020. PubMed ID: 35603567
[TBL] [Abstract] [Full Text] [Related]
6. Manipulating Estrogenic/Anti-Estrogenic Activity of Triphenylethylenes towards Development of Novel Anti-Neoplastic SERMs.
Elnakib HE; Ramsis MM; Albably NO; Vector MA; Weigand JJ; Schwedtmann K; Wober J; Zierau O; Vollmer G; Abadi AH; Ahmed NS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830456
[TBL] [Abstract] [Full Text] [Related]
7. 3-Methyl-imidazo[2,1-b]thiazole derivatives as a new class of antifolates: Synthesis, in vitro/in vivo bio-evaluation and molecular modeling simulations.
Ewida MA; Ewida HA; Ahmed MS; Allam HA; ElBagary RI; George RF; Georgey HH; El-Subbagh HI
Bioorg Chem; 2021 Oct; 115():105205. PubMed ID: 34329992
[TBL] [Abstract] [Full Text] [Related]
8. Human cyp2d6 in the brain Is Protective Against Harmine-Induced Neurotoxicity: Evidence from Humanized cyp2d6 Transgenic Mice.
Stocco MR; Tolledo C; Wadji FB; Gonzalez FJ; Miksys S; Tyndale RF
Mol Neurobiol; 2020 Nov; 57(11):4608-4621. PubMed ID: 32761352
[TBL] [Abstract] [Full Text] [Related]
9. Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder.
Shelton RC; Parikh SV; Law RA; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Macaluso M; Hain DT; Aguilar AL; Brown K; Lewis DJ; Jablonski MR; Greden JF
Psychiatry Res; 2020 Aug; 290():113017. PubMed ID: 32485484
[TBL] [Abstract] [Full Text] [Related]
10. Human cyp2d6 Is Functional in brain In Vivo: Evidence from Humanized cyp2d6 Transgenic Mice.
Tolledo C; Stocco MR; Miksys S; Gonzalez FJ; Tyndale RF
Mol Neurobiol; 2020 Jun; 57(6):2509-2520. PubMed ID: 32189192
[TBL] [Abstract] [Full Text] [Related]
11. brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein).
van Hoppe S; Jamalpoor A; Rood JJM; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
Pharmacol Res; 2019 Aug; 146():104297. PubMed ID: 31175939
[TBL] [Abstract] [Full Text] [Related]
12. Multi-site investigation of strategies for the clinical implementation of cyp2d6 genotyping to guide drug prescribing.
Cavallari LH; Van Driest SL; Prows CA; Bishop JR; Limdi NA; Pratt VM; Ramsey LB; Smith DM; Tuteja S; Duong BQ; Hicks JK; Lee JC; Obeng AO; Beitelshees AL; Bell GC; Blake K; Crona DJ; Dressler L; Gregg RA; Hines LJ; Scott SA; Shelton RC; Weitzel KW; Johnson JA; Peterson JF; Empey PE; Skaar TC;
Genet Med; 2019 Oct; 21(10):2255-2263. PubMed ID: 30894703
[TBL] [Abstract] [Full Text] [Related]
13. Potential role of cyp2d6 in the central nervous system.
Cheng J; Zhen Y; Miksys S; Beyoğlu D; Krausz KW; Tyndale RF; Yu A; Idle JR; Gonzalez FJ
Xenobiotica; 2013 Nov; 43(11):973-84. PubMed ID: 23614566
[TBL] [Abstract] [Full Text] [Related]
14. Metabolic activity in the insular cortex and hypothalamus predicts hot flashes: an FDG-PET study.
Joffe H; Deckersbach T; Lin NU; Makris N; Skaar TC; Rauch SL; Dougherty DD; Hall JE
J Clin Endocrinol Metab; 2012 Sep; 97(9):3207-15. PubMed ID: 22723326
[TBL] [Abstract] [Full Text] [Related]
15. cyp2d6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application.
van der Merwe N; Bouwens CS; Pienaar R; van der Merwe L; Yako YY; Geiger DH; Kotze MJ
Metab Brain Dis; 2012 Sep; 27(3):319-26. PubMed ID: 22638694
[TBL] [Abstract] [Full Text] [Related]
16. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
Scheffler M; Di Gion P; Doroshyenko O; Wolf J; Fuhr U
Clin Pharmacokinet; 2011 Jun; 50(6):371-403. PubMed ID: 21553932
[TBL] [Abstract] [Full Text] [Related]
17. Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1).
Teft WA; Mansell SE; Kim RB
Drug Metab Dispos; 2011 Mar; 39(3):558-62. PubMed ID: 21148080
[TBL] [Abstract] [Full Text] [Related]
18. Using the literature-based discovery paradigm to investigate drug mechanisms.
Ahlers CB; Hristovski D; Kilicoglu H; Rindflesch TC
AMIA Annu Symp Proc; 2007 Oct; 2007():6-10. PubMed ID: 18693787
[TBL] [Abstract] [Full Text] [Related]
19. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
Cacabelos R
Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
[TBL] [Abstract] [Full Text] [Related]
20. cyp2d6 genetic polymorphisms are associated with susceptibility to pituitary tumors.
Gomes L; Lemos MC; Paiva I; Ribeiro C; Carvalheiro M; Regateiro FJ
Acta Med Port; 2005; 18(5):339-43. PubMed ID: 16611538
[TBL] [Abstract] [Full Text] [Related]
[Next]
